Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the ...

(Bloomberg) -- WuXi AppTec Co. posted better-than-expected third-quarter revenue despite concerns over a US bill seeking to ...

NOVATO, Calif. - Ultragenyx Pharmaceutical Inc. (NASDAQ: NASDAQ:RARE), a $4.08 billion market cap biotechnology company with 27% revenue growth in the past year, today unveiled new data indicating ...

The company’s innovative use of the Varian ProBeam Compact proton therapy system, operational since June 2023, is seen as a key driver of this growth. Despite a loss of $37.4 million ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

FY2025 revenue reached $977 million, up 16%, with $165M net income. Growth fueled by NRT portfolio and global generics expansion.

The Downers Grove-based physical therapy clinic operator insists a low market capitalization that led to its delisting isn't ...

Vantive builds on a 70-year legacy of kidney care leadership and innovation, with a singular focus on empowering patients and care teams with ...

“In 2024 we grew our business with four products in five indications globally, exceeding the updated revenue guidance we ... launch of our first gene therapy, in Sanfilippo syndrome, and to ...